The Department of Health and Social Care (DHSC) recently announced a consultation for a review of the statutory scheme for branded medicines (the ‘Statutory Scheme’).
The proposed amendments (1) increase the allowed growth rate under the Scheme; (2) add new exemptions, including one for new active substances; and (3) introduce a lifecycle adjustment mechanism to control spending on older branded medicines.
In this article, Alex Denoon and Vivien Zhu provide insight into the announced consultation, providing details of the proposals which include proposed payment percentages and product-specific rules.
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2024-08-23-11-31-07-354-66c872fb971eecc249d83d40.png)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2024-08-01-13-11-10-549-66ab896ee543bf94f9636c73.png)
